ArticleJournal of drug delivery2013
Lipid-based nanoparticles in cancer diagnosis and therapy.
Article in Journal of drug delivery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Ionizable lipid nanoparticles with functionalized PEG-lipids increase retention in the tumor microenvironment.Molecular therapy. Methods & clinical development · 2025Article
- Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward.Journal of cardiovascular translational research · 2025Review
- Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy.International journal of molecular sciences · 2022Review
- Optimized Apamin-Mediated Nano-Lipidic Carrier Potentially Enhances the Cytotoxicity of Ellagic Acid against Human Breast Cancer Cells.International journal of molecular sciences · 2022Article
- Piceatannol-Loaded Bilosome-Stabilized Zein Protein Exhibits Enhanced Cytostatic and Apoptotic Activities in Lung Cancer Cells.Pharmaceutics · 2021Article
- Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics.Current research in pharmacology and drug discovery · 2021Review
- Piceatannol-Loaded Emulsomes Exhibit Enhanced Cytostatic and Apoptotic Activities in Colon Cancer Cells.Antioxidants (Basel, Switzerland) · 2020Article
- Article
- Delivery strategies of cancer immunotherapy: recent advances and future perspectives.Journal of hematology & oncology · 2019Review
- Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019Review
- GE11 Peptide as an Active Targeting Agent in Antitumor Therapy: A Minireview.Pharmaceutics · 2017Review
- Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs.Journal of nanobiotechnology · 2017Article
- Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo.Scientific reports · 2017Article
- Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents.Nanoscale · 2017Article
- The Optimized Fabrication of Nanobubbles as Ultrasound Contrast Agents for Tumor Imaging.Scientific reports · 2015Article
- Cationic liposome-nucleic acid complexes for gene delivery and gene silencing.New journal of chemistry = Nouveau journal de chimie · 2014Article
- Preclinical evaluation of an O(6)-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains.American journal of translational research · 2014Article
- An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment.Technology in cancer research & treatmentReview
- Nanomedical engineering: shaping future nanomedicines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today, researchers are constantly developing new nanomaterials, nanodevices, and nanoparticles to meet unmet needs in the delivery of therapeutic agents and imaging agents for cancer therapy and diagnosis, respectively. Of particular interest here are lipid-based nanoparticles (LNPs) that are genuine particles (approximately 100 nm in dimension) assembled from varieties of lipid and other chemical components that act collectively to overcome biological barriers (biobarriers), in order for LNPs to preferentially accumulate in or around disease-target cells for the functional delivery of therapeutic agents for treatment or of imaging agents for diagnosis. The capabilities of these LNPs will clearly vary depending on functional requirements, but the nanoscale allows for an impressive level of diversity in capabilities to enable corresponding LNPs to address an equally diverse range of functional requirements. Accordingly, LNPs should be considered appropriate vehicles to provide an integrated, personalized approach to cancer diagnosis and therapy in future cancer disease management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.